Oxford Biomedica (LON:OXB) Hits New 52-Week Low – Here’s What Happened

Oxford Biomedica plc (LON:OXB – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 431 and last traded at GBX 436.55, with a volume of 1907452 shares changing hands. The stock had previously closed at GBX 524.

Analysts Set New Price Targets

OXB has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft lowered shares of Oxford Biomedica to a “hold” rating and cut their price target for the company from GBX 800 to GBX 595 in a research note on Tuesday, August 18th. Jefferies Financial Group reissued a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Finally, Royal Bank Of Canada reduced their target price on Oxford Biomedica from GBX 1,140 to GBX 900 and set an “outperform” rating for the company in a research note on Monday, August 10th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Oxford Biomedica currently has a consensus rating of “Moderate Buy” and an average price target of GBX 580.85.

Get Oxford Biomedica alerts:

Check Out Our Latest Research Report on Oxford Biomedica

Oxford Biomedica Trading Down 14.7%

The company’s fifty day simple moving average is GBX 569.98 and its 200-day simple moving average is GBX 609.04. The firm has a market capitalization of £541.04 million, a PE ratio of -16.60 and a beta of 1.10. The company has a debt-to-equity ratio of 162.16, a current ratio of 2.20 and a quick ratio of 1.67.

About Oxford Biomedica

(Get Free Report)

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

Featured Articles

• Five stocks we like better than Oxford Biomedica
• NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
• Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
• Medtronic’s Stars Are Aligning for a Price Recovery
• Analysts See Major Upside for This Top-10 Performing S&P 500 Stock

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.